Advantages of α-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 5, 1998, Pages 1515-1522

  Johnston, Peter S ^a,e   Lebovitz, Harold E ^b   Coniff, Robert F ^a   Simonson, Donald C ^c   Raskin, Philip ^d   Munera, Catherine L ^a  

^a BAYER CORPORATION   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e PURDUE PHARMA L P   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; GLIBENCLAMIDE; HEMOGLOBIN A1C; MIGLITOL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

AGED; ALPHA-GLUCOSIDASES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; FASTING; FEMALE; FOOD; GLUCOSAMINE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; IMINO PYRANOSES; INSULIN; KINETICS; MALE;

EID: 0031755644     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.83.5.1515     Document Type: Article

References (19)

1. Naliboff BD, Rosenthal M. 1989 Effects of age on complications in adult-onset-diabetes. J Am Geriatr Soc. 37:838-843.
2. Morley JE, Mooradian AD, Rosenthal MJ, Kaiser FE. 1987 Diabetes mellitus in elderly patients - is it different? Am J Med. 83:533-544.
3. Morley JE, Kaiser FE. 1990 Unique aspects of diabetes mellitus in the elderly. Clin Geriatr Med. 6:693-702.
4. Davidson MB. 1991 Diagnosis and treatment of diabetes mellitus in the elderly. In: Davidson MB, ed. Diabetes mellitus, diagnosis and treatment. 3rd ed. New York: Churchill Livingstone; 566-576.
5. Brodows RG. 1992 Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care. 15:75-80.
6. Lipson W. 1986 Diabetes in the elderly: diagnosis, pathogenesis, and therapy Am J Med 80(Suppl 5A):10-21.
7. 1c. Gerontology. 37:648-650.
8. Meneilly GS, Minaker KC, Elahi D, et al. 1987 Insulin action in aging man: evidence for tissue-specific differences at low physiologic insulin level. J Gerontol. 42:196-201.
9. Jarrett RJ, McCarney P, Keen H. 1982 The Bedford survey: ten-year mortality rates in newly diagnosed diabetes, borderline diabetes and normoglycemic controls, and risk indices for coronary heart disease in borderline diabetes. Diabetologia. 22:79-84.
10. Johnston PS, Coniff RF, Hoogwerf BJ, Santiago JV, Pi-Sunyer FX, Krol A. 1994 Effects of the carbohydrase inhibitor miglitol in sulfonylurea-treated NIDDM patients. Diabetes Care. 17:20-29.
11. Asplund K, Wilholm B-E, Lithner F. 1983 Glibenclamide-associated hypoglycemia: a report on 57 cases. Diabetologia. 24:412-417.
12. Pulsinelli WA, Levy DE, Sigsbee B, Scherer P, Plum F. 1983 Increased damage after ischemic stroke in patients with hyperglycemia with or without established diabetes mellitus. Am J Med. 74:540-544.
13. Heinsimer JA, Lefkowitz RJ. 1985 The impact of aging in adrenergic receptor function: clinical and biochemical aspects. J Am Geriatr Soc. 33:184-188.
14. University Group Diabetes Program. 1970 A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. Diabetes. 19:747-830.
15. Coniff RF, Johnston PS, Knowles L, Krol A. 1996 Long-term effects of the α-glucosidase inhibitor miglitol (BAY m 1099) in NIDDM patients treated with maximum-dose sulfonylurea. Diabetes 45(Suppl 2):221A.
16. Johnston P, Feig P, Coniff R. 1997 Treatment of Afro-American NIDDM patients with α-glucosidase inhibition. Diabetes 46(Suppl 1):156A.
17. Davidson JA, Johnston P, Feig P, Coniff R. 1997 Treatment of Hispanic-American NIDDM patients with α-glucosidase inhibition. Diabetes 46(Suppl 1):156A.
18. Fontbonne A, Charles MA, Thibault N, et al. 1991 Hyperinsulinemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up. Diabetologia. 34:356-361.
19. Leahy JL. 1996 Impaired β-cell function with chronic hyperglycemia: the "overworked β-cell" hypothesis. Diabetes Reviews. 4:298-319.